Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial

Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial

Abstract Background Intestinal microbiota restoration can be achieved by complementing a subject’s perturbed microbiota with that of a healthy donor. Recurrent Clostridioides difficile infection (rCDI) is one key application of such treatment. Another emerging application of interest is reducing ant...

Full description

Bibliographic Details
Main Authors: Suryang Kwak, JooHee Choi, Tiffany Hink, Kimberly A. Reske, Kenneth Blount, Courtney Jones, Margaret H. Bost, Xiaoqing Sun, Carey-Ann D. Burnham, Erik R. Dubberke, Gautam Dantas, for the CDC Prevention Epicenter Program
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Microbiome
Subjects:
Microbiota-based therapy
Placebo
Microbiome
Resistome
Clostridioides difficile infection
Antibiotic-resistant organisms
Online Access:http://link.springer.com/article/10.1186/s40168-020-00907-9

Internet

http://link.springer.com/article/10.1186/s40168-020-00907-9

Similar Items